Actinium Pharmaceuticals (NYSE:ATNM) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Actinium Pharmaceuticals (NYSE:ATNM) announced its quarterly earnings data on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02, Yahoo Finance reports.

Actinium Pharmaceuticals Stock Down 26.8 %

NYSE ATNM traded down $0.77 during mid-day trading on Wednesday, reaching $2.10. 1,989,268 shares of the company’s stock traded hands, compared to its average volume of 474,034. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24. The firm has a market cap of $62.54 million, a PE ratio of -1.29 and a beta of 0.20.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday. Maxim Group cut their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $16.00 to $2.00 in a report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.43.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.